AR083023A1 - Compuestos de piridina y una composicion farmaceutica que los comprende - Google Patents
Compuestos de piridina y una composicion farmaceutica que los comprendeInfo
- Publication number
- AR083023A1 AR083023A1 ARP110103396A ARP110103396A AR083023A1 AR 083023 A1 AR083023 A1 AR 083023A1 AR P110103396 A ARP110103396 A AR P110103396A AR P110103396 A ARP110103396 A AR P110103396A AR 083023 A1 AR083023 A1 AR 083023A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- group
- hydrogen
- heterocycle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/58—Amidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Abstract
Los compuestos de la fórmula (1) sirven para tratar un trastorno sensible al bloqueo de canales de sodio. Los compuestos son especialmente útiles para tratar el dolor, y como neuroprotectores.Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1) o una sal, solvato o profármaco de este aceptables desde el punto de vista farmacéutico, en donde Z1 se selecciona del grupo que consiste en N y N-óxido, y Z2 es CR1b; o Z1 es CR1b, y Z2 se selecciona del grupo que consiste en N y N-óxido; R1a y R1b, que son idénticos o diferentes, se seleccionan del grupo que consiste en: hidrógeno; halógeno; hidroxi; ciano; alquilo opcionalmente sustituido; alcoxi; haloalcoxi; y haloalquilo; A1 se selecciona del grupo que consiste en: cicloalquilo opcionalmente sustituido; heterociclo opcionalmente sustituido; arilo opcionalmente sustituido; y heteroarilo opcionalmente sustituido; X se selecciona del grupo que consiste en: -O-; -S-; -SO-; -SO2-; -(CR2R3)j-; -NR4-; y -SO2NH-; en donde: en cada caso, R2 y R3, que son idénticos o diferentes, se seleccionan del grupo que consiste en hidrógeno, flúor y alquilo opcionalmente sustituido; o cada R2 y R3 se toman juntos para formar un grupo oxo; o cada R2 y R3, junto con el átomo de carbono al que están unidos, forman un cicloalquilo opcionalmente sustituido o heterociclo opcionalmente sustituido de 3 a 8 miembros; j es 0, 1, 2 ó 3; y R4 se selecciona del grupo que consiste en hidrógeno y alquilo opcionalmente sustituido; A2 se selecciona del grupo que consiste en arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; G se selecciona del grupo que consiste en hidrógeno; alquilo; ciano; y los restos de fórmula (G-1) a (G-5); en donde: R5a y R5b, que son idénticos o diferentes, se seleccionan del grupo que consiste en: hidrógeno; alquilo opcionalmente sustituido; cicloalquilo opcionalmente sustituido; heterociclo opcionalmente sustituido; arilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; aralquilo; hidroxialquilo; (ciano)alquilo; (heterociclo)alquilo; (heteroaril)alquilo; (amino)alquilo; (alquilamino)alquilo; (dialquilamino)alquilo; y -(CH2CH2O)m-R15a; o R5a y R5b, junto con el átomo de nitrógeno al que están unidos, forman un heterociclo de 3 a 8 miembros opcionalmente sustituido; R6a y R6b, que son idénticos o diferentes, se seleccionan del grupo que consiste en: hidrógeno; alquilo opcionalmente sustituido; cicloalquilo opcionalmente sustituido; heterociclo opcionalmente sustituido; arilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; hidroxialquilo; (heterociclo)alquilo; (heteroaril)alquilo; (amino)alquilo; (alquilamino)alquilo; (dialquilamino)alquilo; (carboxamido)alquilo; (ciano)alquilo; y (CH2CH2O)n-R15b; R6a y R6b, junto al átomo de nitrógeno al que están unidos, forman un heterociclo de 3 a 8 miembros opcionalmente sustituido; R7 se selecciona del grupo que consiste en: hidrógeno; alquilo opcionalmente sustituido; cicloalquilo opcionalmente sustituido; heterociclo opcionalmente sustituido; arilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; (heterociclo)alquilo; (heteroaril)alquilo; (amino)alquilo; (alquilamino)alquilo; (dialquilamino)alquilo; y (CH2CH2O)o-R15c; R8a y R8b, que son idénticos o diferentes, se seleccionan del grupo que consiste en: hidrógeno; alquilo opcionalmente sustituido; y (CH2CH2O)p-R15d; L se selecciona del grupo que consiste en -O- y -NR16-; R9 se selecciona del grupo que consiste en hidrógeno, alquilo y -(CH2CH2O)q-R15e; R15a, R15b, R15c, R15d y R15e, que son idénticos o diferentes, se seleccionan del grupo que consiste en hidrógeno y alquilo opcionalmente sustituido; R16 se selecciona del grupo que consiste en hidrógeno y alquilo opcionalmente sustituido; m, n, o, p y q son cada uno, independientemente, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 u 11; w es 0, 1, 2, 3, 4 ó 5; x y son cada uno, independientemente, 1, 2, 3, ó 4; E se selecciona del grupo que consiste en hidrógeno; halógeno; alquilo; heteroarilo opcionalmente sustituido; heterociclo opcionalmente sustituido; hidroxialquilo; y los restos de fórmula (E-1) a (E-6); en donde: R17a y R17b, son idénticos o diferentes, se seleccionan del grupo que consiste en: hidrógeno; alquilo opcionalmente sustituido; -SO2R24a; -COR24b; arilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; (heterociclo)alquilo; (heteroaril)alquilo; (amino)alquilo; (alquilamino)alquilo; (dialquilamino)alquilo; (carboxamido)alquilo; (ciano)alquilo; e hidroxialquilo; o R17a y R17b junto con el átomo de nitrógeno al que están unidos, forman un heterociclo de 3 a 8 miembros opcionalmente sustituido; R18a y R18b, que son idénticos o diferentes, se seleccionan del grupo que consiste en: hidrógeno; alquilo opcionalmente sustituido; cicloalquilo opcionalmente sustituido; arilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; (heterociclo)alquilo; (heteroaril)alquilo; y (dialquilamino)alquilo; o R18a y R18b junto con el átomo de nitrógeno al que están unidos, forman un heterociclo de 3 a 8 miembros opcionalmente sustituido; R19 se selecciona del grupo que consiste en hidrógeno y alquilo opcionalmente sustituido; R20a y R20b que son idénticos o diferentes, se seleccionan del grupo que consiste en hidrógeno y alquilo opcionalmente sustituido, en donde al menos uno de R20a y R20b es alquilo opcionalmente sustituido; R21a se selecciona del grupo que consiste en hidrógeno y alquilo; R21b y R21c, que son idénticos o diferentes, se seleccionan del grupo que consiste en: hidrógeno; alquilo opcionalmente sustituido; cicloalquilo opcionalmente sustituido; arilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; (heterociclo)alquilo; (heteroaril)alquilo; y (dialquilamino)alquilo; o R21b y R21c junto con el átomo de nitrógeno al que están unidos, forman un heterociclo de 3 a 8 miembros opcionalmente sustituido; R22 se selecciona del grupo que consiste en hidrógeno y alquilo; R24a se selecciona del grupo que consiste en alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; R24b se selecciona del grupo que consiste en alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; t y u son cada uno, independientemente, 0, 1, 2 ó 3; y v es 1, 2 ó 3; en donde: I) G y E no pueden ser ambos hidrógeno; II) cuando G es alquilo, entonces E no es halógeno; III) cuando G es el resto de fórmula (G-1), w es 0, y E es el resto de fórmula (E-1); entonces R17a no es hidrógeno o alquilo cuando R17b es hidrógeno o alquilo; IV) cuando G es el resto de fórmula (G-1), w es 0, y E es el resto de fórmula (E-2), entonces u es 1, 2 ó 3; V) cuando G es el resto de fórmula (G-1), y R5a y R5b, junto con el átomo de nitrógeno al que están unidos, forman un heterociclo de 3 a 8 miembros opcionalmente sustituido, entonces dichos sustituyentes opcionales se seleccionan del grupo que consiste en halo, nitro, ciano, hidroxi, amino, alquilamino, dialquilamino, haloalquilo, hidroxialquilo, alcoxi, haloalcoxi, ariloxi, aralquiloxi, alquiltio, alquilcarbonilo, arilcarbonilo, ureido, guanidino, alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterociclo opcionalmente sustituido, alcoxialquilo, (amino)alquilo, hidroxialquilamino, (alquilamino)alquilo, (dialquilamino)alquilo, (ciano)alquilo, (carboxamido)alquilo, mercaptoalquilo, (heterociclo)alquilo y (heteroaril)alquilo; VI) cuando G es el resto de fórmula (G-1) y w es 0, entonces E no es un grupo morfolinilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38413610P | 2010-09-17 | 2010-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR083023A1 true AR083023A1 (es) | 2013-01-23 |
Family
ID=44903282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110103396A AR083023A1 (es) | 2010-09-17 | 2011-09-16 | Compuestos de piridina y una composicion farmaceutica que los comprende |
Country Status (12)
Country | Link |
---|---|
US (2) | US9056832B2 (es) |
EP (2) | EP2616441B1 (es) |
JP (1) | JP2013538227A (es) |
KR (1) | KR20130056345A (es) |
CN (1) | CN103153955A (es) |
AR (1) | AR083023A1 (es) |
AU (1) | AU2011303597A1 (es) |
BR (1) | BR112013006272A2 (es) |
CA (1) | CA2811479A1 (es) |
IL (1) | IL225185A0 (es) |
MX (1) | MX2013003101A (es) |
WO (1) | WO2012035421A2 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ590887A (en) | 2008-08-04 | 2012-09-28 | Chdi Foundation Inc | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
EP2528441A4 (en) | 2010-01-25 | 2013-07-10 | Chdi Foundation Inc | CERTAIN KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF |
US9212139B2 (en) | 2010-06-16 | 2015-12-15 | Purdue Pharma, L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
WO2012007836A1 (en) | 2010-07-16 | 2012-01-19 | Purdue Pharma .Lp. | Pyridine compounds as sodium channel blockers |
US9056832B2 (en) | 2010-09-17 | 2015-06-16 | Purdue Pharma L.P. | Pyridine compounds and the users thereof |
JP2013540130A (ja) | 2010-10-05 | 2013-10-31 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのキナゾリン化合物 |
JP2014500303A (ja) * | 2010-12-22 | 2014-01-09 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としての置換ピリジン |
AU2012300246A1 (en) | 2011-08-30 | 2014-03-06 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
CN106518845B (zh) | 2011-08-30 | 2019-09-13 | Chdi基金会股份有限公司 | 犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法 |
EP2753606B1 (en) | 2011-09-02 | 2017-07-05 | Purdue Pharma LP | Pyrimidines as sodium channel blockers |
US9388137B2 (en) | 2011-10-31 | 2016-07-12 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
US9181185B2 (en) | 2011-10-31 | 2015-11-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
US9133131B2 (en) | 2011-11-15 | 2015-09-15 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
AU2013203824A1 (en) | 2012-03-16 | 2013-10-03 | Purdue Pharma L.P. | Substituted pyridines and pryimidines as sodium channel blockers |
WO2014072809A2 (en) | 2012-11-09 | 2014-05-15 | Purdue Pharma L.P. | Benzomorphan analogs and the use thereof |
EP2935257B1 (en) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
JP6110516B2 (ja) * | 2013-03-04 | 2017-04-05 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのピリミジンカルボキサミド |
US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
EP3666274A1 (en) * | 2013-03-15 | 2020-06-17 | Purdue Pharma LP | Carboxamide derivatives and use thereof |
MA38661A1 (fr) | 2013-06-27 | 2017-03-31 | Pfizer | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine |
US9359330B2 (en) | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
US9884865B2 (en) | 2013-08-26 | 2018-02-06 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
JP6615752B2 (ja) * | 2013-09-30 | 2019-12-04 | グアンジョウ・イノケア・ファーマ・テク・カンパニー・リミテッド | Btkの置換ニコチンイミド阻害剤およびそれらの調製、ならびにがん、炎症および自己免疫疾患の治療における使用 |
US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
EP3083606B1 (en) | 2013-12-20 | 2020-10-28 | Purdue Pharma LP | Pyrimidines and use thereof |
US9695144B2 (en) | 2013-12-23 | 2017-07-04 | Purdue Pharma L.P. | Dibenzazepine derivatives and use thereof |
WO2015099841A1 (en) | 2013-12-23 | 2015-07-02 | Purdue Pharma L.P. | Indazoles and use thereof |
EP3089978B1 (en) | 2013-12-30 | 2018-08-29 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
US10047075B2 (en) | 2014-01-24 | 2018-08-14 | Purdue Pharma L.P. | Pyridines and pyrimidines and use thereof |
WO2015123398A1 (en) | 2014-02-12 | 2015-08-20 | Purdue Pharma L.P. | Isoquinoline derivatives and use thereof |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
JP6386088B2 (ja) | 2014-05-06 | 2018-09-05 | パーデュー、ファーマ、リミテッド、パートナーシップ | ベンゾモルファン類似体及びその使用 |
MA40170A (fr) | 2014-06-13 | 2017-04-19 | Purdue Pharma Lp | Dérivés hétérocycliques de morphinan et leur utilisation |
CA2951697A1 (en) | 2014-06-13 | 2015-12-17 | Purdue Pharma L.P. | Azamophinan derivatives and use thereof |
US10258621B2 (en) | 2014-07-17 | 2019-04-16 | Chdi Foundation, Inc. | Methods and compositions for treating HIV-related disorders |
CA2977367A1 (en) | 2015-02-19 | 2016-08-25 | Purdue Pharma L.P. | Methods and compositions for decreasing gastric emptying |
US10745402B2 (en) | 2017-01-02 | 2020-08-18 | Purdue Pharma L.P. | Morphinan derivatives and use thereof |
CN108358966B (zh) * | 2018-03-05 | 2020-04-28 | 南京工业大学 | 一种靶向-增强线粒体功能药物Mito-VB3及其制备方法和应用 |
US11008302B2 (en) * | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
EP3921315A1 (en) * | 2019-02-07 | 2021-12-15 | Nouryon Chemicals International B.V. | Process for manufacturing alkyleneamine compounds |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4697012A (en) * | 1984-07-25 | 1987-09-29 | Merck & Co., Inc. | Morpholino pyridyl thiazole compound |
DE3922735A1 (de) * | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
JP3385387B2 (ja) * | 1992-05-29 | 2003-03-10 | 大塚製薬株式会社 | チアゾール誘導体 |
US5639770A (en) * | 1992-05-29 | 1997-06-17 | Otsuka Pharmaceutical Co., Ltd. | Thiazole derivatives |
WO1993024472A1 (en) * | 1992-05-29 | 1993-12-09 | Otsuka Pharmaceutical Co., Ltd. | Thiazole derivative |
EP0672042B1 (en) * | 1993-10-01 | 2006-05-03 | Novartis AG | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
WO1995009847A1 (en) * | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
DE4337322A1 (de) * | 1993-11-02 | 1995-05-04 | Basf Ag | Pyrid-N-oxid substituierte Salicylaldehyd- bzw. Salicylsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide |
AT400845B (de) | 1993-12-06 | 1996-03-25 | Chem Pharm Forsch Gmbh | Neue thienothiazinderivate, ein verfahren zu ihrer herstellung und ihre verwendung |
DE4430638A1 (de) * | 1994-08-29 | 1996-03-07 | Bayer Ag | Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel |
AU6111796A (en) | 1995-06-12 | 1997-01-09 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor |
JP2001526648A (ja) | 1997-04-22 | 2001-12-18 | コセンシス・インコーポレイテッド | 炭素環及びヘテロ環で置換されたセミカルバゾン及びチオセミカルバゾン、及びその使用 |
WO1999024440A1 (en) | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
IL136044A (en) | 1997-11-21 | 2005-08-31 | Euro Celtique Sa | 2-aminoacetamide derivatives and pharmaceutical compositions containing the same |
US6281211B1 (en) | 1999-02-04 | 2001-08-28 | Euro-Celtique S.A. | Substituted semicarbazides and the use thereof |
NZ514756A (en) | 1999-03-26 | 2004-04-30 | Euro Celtique S | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
ATE303162T1 (de) | 1999-04-09 | 2005-09-15 | Euro Celtique Sa | Natrium kanalblocker zusammensetzungen und deren verwendung |
AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
BR0108819A (pt) | 2000-03-24 | 2002-12-10 | Euro Celtique Sa | Pirazóis triazóis e tetrazóis substituìdos de arila, e o uso dos mesmos |
US6335354B2 (en) | 2000-03-31 | 2002-01-01 | Cocensys Inc. | Aminopyridines and methods of using thereof |
AU5889701A (en) | 2000-06-05 | 2001-12-17 | Dong A Pharm Co Ltd | Novel oxazolidinone derivatives and a process for the preparation thereof |
PL359416A1 (en) * | 2000-07-18 | 2004-08-23 | Yamanouchi Pharmaceutical Co, Ltd. | Medicine comprising dicyanopyridine derivative |
MXPA04000411A (es) | 2001-07-16 | 2004-03-18 | Euro Celtique Sa | Tiazolidinonas arilo sustituidas y uso de las mismas. |
AR036873A1 (es) * | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
CA2468067A1 (en) * | 2001-11-30 | 2003-06-12 | Merck & Co., Inc. | Metabotropic glutamate receptor-5 modulators |
MXPA04008901A (es) | 2002-03-13 | 2004-11-26 | Euro Celtique Sa | Pirimidinas arilo sustituidas y el uso de las mismas. |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
ATE447404T1 (de) | 2002-03-29 | 2009-11-15 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
GB0217787D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | C ompounds |
KR20050026023A (ko) | 2002-07-31 | 2005-03-14 | 유로-셀티큐 에스.에이. | 아릴 치환된 히단토인 화합물 및 그들의 나트륨 채널차단제로서의 용도 |
JP2006504660A (ja) | 2002-07-31 | 2006-02-09 | ユーロ−セルティーク エス.エイ. | アリール置換ベンゾイミダゾール類およびナトリウムチャネルブロッカーとしてのそれらの使用 |
US20040152696A1 (en) | 2002-08-01 | 2004-08-05 | Euro-Celtique S.A. | 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers |
US7122580B2 (en) | 2002-08-09 | 2006-10-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
SE0203654D0 (sv) * | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | New compounds |
US20040142978A1 (en) * | 2002-12-12 | 2004-07-22 | Pharmacia Corporation | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 |
US20040142379A1 (en) | 2003-01-16 | 2004-07-22 | Carlsberg Research Laboratory | Affinity fishing for ligands and proteins receptors |
US20060293339A1 (en) * | 2003-03-24 | 2006-12-28 | Chakravarty Prasun K | Biaryl substituted 6-membered heterocycles as sodium channel blockers |
CA2521399A1 (en) | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
EP1654245A1 (en) | 2003-08-07 | 2006-05-10 | Bayer Pharmaceuticals Corporation | Benzofuran derivatives useful for treating hyper-proliferative disorders |
WO2005080393A1 (en) | 2004-02-14 | 2005-09-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
BRPI0508243A (pt) | 2004-03-04 | 2007-07-24 | Kissei Pharmaceutical | derivados de anéis fundidos nitrogenados, composições medicinais contendo os derivados e uso destas como drogas |
WO2005107760A1 (en) | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
DE602005016272D1 (de) * | 2004-08-27 | 2009-10-08 | Astellas Pharma Inc | 2-phenylpyridinderivat |
TW200621251A (en) | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
US20060122210A1 (en) | 2004-11-18 | 2006-06-08 | Wenqing Yao | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same |
US20060281763A1 (en) | 2005-03-25 | 2006-12-14 | Axon Jonathan R | Carboxamide inhibitors of TGFbeta |
EP2527337A1 (en) | 2005-04-14 | 2012-11-28 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
WO2007039146A1 (en) | 2005-09-23 | 2007-04-12 | Smithkline Beecham Corporation | 4-carboxy pyrazole derivatives as anti-viral agents |
PE20070619A1 (es) | 2005-09-27 | 2007-07-02 | Wyeth Corp | TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA |
TW200732313A (en) | 2005-12-15 | 2007-09-01 | Astrazeneca Ab | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators |
GB0607196D0 (en) * | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
CA2672940A1 (en) * | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
JP5461197B2 (ja) * | 2007-02-02 | 2014-04-02 | ベイラー カレッジ オブ メディスン | 代謝障害を処置するための組成物および方法 |
WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
US8293747B2 (en) | 2007-07-19 | 2012-10-23 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
CN101815710A (zh) * | 2007-08-02 | 2010-08-25 | 美国辉瑞有限公司 | 嘧啶和吡啶衍生物及其药物应用和组合物 |
EP2220091B1 (en) | 2007-12-14 | 2012-07-25 | Ardea Biosciences, Inc. | Reverse transcriptase inhibitors |
TW200940537A (en) * | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
CN102015723B (zh) * | 2008-03-05 | 2014-07-30 | 梅特希尔基因公司 | 蛋白酪氨酸激酶活性的抑制剂 |
EP2254892B1 (en) * | 2008-03-26 | 2014-04-23 | Global Alliance For Tb Drug Development | Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones |
JP2011184298A (ja) * | 2008-06-02 | 2011-09-22 | Sanwa Kagaku Kenkyusho Co Ltd | 新規化合物及びその医薬用途 |
GB0813403D0 (en) | 2008-07-22 | 2008-08-27 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
EP2331522B1 (en) * | 2008-08-01 | 2013-09-18 | Purdue Pharma LP | Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof |
JP2011530483A (ja) | 2008-08-12 | 2011-12-22 | 武田薬品工業株式会社 | アミド化合物 |
JP5563985B2 (ja) * | 2008-10-15 | 2014-07-30 | キッセイ薬品工業株式会社 | フェニルイソニコチン酸誘導体及びその医薬用途 |
EP2358371B1 (en) | 2008-10-31 | 2015-02-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
JP2012508723A (ja) * | 2008-11-14 | 2012-04-12 | バイエル・クロップサイエンス・アーゲー | 植物保護剤としての置換(ピリジル)−アジニルアミン誘導体 |
WO2010079443A1 (en) * | 2009-01-12 | 2010-07-15 | Pfizer Limited | Sulfonamide derivatives |
WO2010100475A1 (en) | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
FI20095302A0 (fi) * | 2009-03-24 | 2009-03-24 | Arctic Partners Oy Ab | Luminesenssimääritysmenetelmä |
EP2435080A2 (en) | 2009-05-29 | 2012-04-04 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
RS53626B1 (en) | 2009-06-26 | 2015-04-30 | Pfizer Inc. | HETEROCYCLIC SULFONAMIDES, THEIR USE AND PHARMACEUTICAL COMPOSITIONS |
US8846673B2 (en) * | 2009-08-11 | 2014-09-30 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
US9212139B2 (en) | 2010-06-16 | 2015-12-15 | Purdue Pharma, L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
WO2012007836A1 (en) | 2010-07-16 | 2012-01-19 | Purdue Pharma .Lp. | Pyridine compounds as sodium channel blockers |
US9056832B2 (en) | 2010-09-17 | 2015-06-16 | Purdue Pharma L.P. | Pyridine compounds and the users thereof |
JP2013540130A (ja) | 2010-10-05 | 2013-10-31 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのキナゾリン化合物 |
JP2014500303A (ja) | 2010-12-22 | 2014-01-09 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としての置換ピリジン |
EP2753606B1 (en) | 2011-09-02 | 2017-07-05 | Purdue Pharma LP | Pyrimidines as sodium channel blockers |
US9388137B2 (en) | 2011-10-31 | 2016-07-12 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
US9181185B2 (en) | 2011-10-31 | 2015-11-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
US9133131B2 (en) | 2011-11-15 | 2015-09-15 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
AU2013203824A1 (en) | 2012-03-16 | 2013-10-03 | Purdue Pharma L.P. | Substituted pyridines and pryimidines as sodium channel blockers |
EP2935257B1 (en) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
JP6110516B2 (ja) | 2013-03-04 | 2017-04-05 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのピリミジンカルボキサミド |
EP3666274A1 (en) | 2013-03-15 | 2020-06-17 | Purdue Pharma LP | Carboxamide derivatives and use thereof |
US9359330B2 (en) | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
US9884865B2 (en) | 2013-08-26 | 2018-02-06 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
EP3083606B1 (en) | 2013-12-20 | 2020-10-28 | Purdue Pharma LP | Pyrimidines and use thereof |
WO2015099841A1 (en) | 2013-12-23 | 2015-07-02 | Purdue Pharma L.P. | Indazoles and use thereof |
EP3087057A4 (en) | 2013-12-26 | 2017-06-28 | Purdue Pharma LP | Ring-contracted morphinans and the use thereof |
US10047075B2 (en) | 2014-01-24 | 2018-08-14 | Purdue Pharma L.P. | Pyridines and pyrimidines and use thereof |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
-
2011
- 2011-09-16 US US13/821,732 patent/US9056832B2/en active Active
- 2011-09-16 KR KR1020137009767A patent/KR20130056345A/ko not_active Application Discontinuation
- 2011-09-16 AR ARP110103396A patent/AR083023A1/es unknown
- 2011-09-16 JP JP2013528783A patent/JP2013538227A/ja active Pending
- 2011-09-16 WO PCT/IB2011/002172 patent/WO2012035421A2/en active Application Filing
- 2011-09-16 EP EP11776851.5A patent/EP2616441B1/en active Active
- 2011-09-16 BR BR112013006272A patent/BR112013006272A2/pt not_active IP Right Cessation
- 2011-09-16 MX MX2013003101A patent/MX2013003101A/es not_active Application Discontinuation
- 2011-09-16 AU AU2011303597A patent/AU2011303597A1/en not_active Abandoned
- 2011-09-16 CA CA2811479A patent/CA2811479A1/en not_active Abandoned
- 2011-09-16 CN CN2011800446318A patent/CN103153955A/zh active Pending
- 2011-09-16 EP EP19189601.8A patent/EP3590925B1/en active Active
-
2013
- 2013-03-12 IL IL225185A patent/IL225185A0/en unknown
-
2015
- 2015-05-28 US US14/724,494 patent/US9611222B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL225185A0 (en) | 2013-06-27 |
US9056832B2 (en) | 2015-06-16 |
EP3590925B1 (en) | 2022-03-30 |
EP2616441A2 (en) | 2013-07-24 |
AU2011303597A1 (en) | 2013-04-11 |
MX2013003101A (es) | 2013-09-26 |
US9611222B2 (en) | 2017-04-04 |
EP3590925A1 (en) | 2020-01-08 |
US20130303526A1 (en) | 2013-11-14 |
WO2012035421A2 (en) | 2012-03-22 |
JP2013538227A (ja) | 2013-10-10 |
CN103153955A (zh) | 2013-06-12 |
CA2811479A1 (en) | 2012-03-22 |
WO2012035421A3 (en) | 2012-09-07 |
EP2616441B1 (en) | 2019-08-07 |
US20150259293A1 (en) | 2015-09-17 |
BR112013006272A2 (pt) | 2019-09-24 |
KR20130056345A (ko) | 2013-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR083023A1 (es) | Compuestos de piridina y una composicion farmaceutica que los comprende | |
RS53342B (en) | DERIVATIVES OF PRIVATE AND INHIBITORIES MEK | |
WO2007044724A3 (en) | Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3 | |
NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
UA97639C2 (ru) | ОКТАГИДРОПИРОЛО[3,4-b]ПИРРОЛЬНЫЕ ПРОИЗВОДНЫЕ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ ГИСТАМИНА-3 | |
IL185844A0 (en) | I-acetic acid-indole derivatives with pgd2 antagonist activity | |
MX2009005217A (es) | Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos. | |
MX371167B (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
ES2570784T3 (es) | Piridinas sustituidas como bloqueadores de los canales de sodio | |
ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
WO2008148849A8 (en) | Piperidine/piperazine derivatives | |
MX344669B (es) | Agente antiplaquetas novedoso. | |
RS20060201A (en) | 1,1,1,-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo | |
TW200833675A (en) | Nicotinamide derivatives | |
MX2015008971A (es) | Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor. | |
MX2009008540A (es) | Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina. | |
MX2013004407A (es) | Derivado de piridina y agente medicinal. | |
MX2009013833A (es) | Compuestos de piridazina cristalina. | |
TW200612964A (en) | Methods for preparing p2x7 inhibitors | |
TN2011000380A1 (en) | Triazolopyridine derivatives as p38 map kinase inhibitors | |
AR054688A1 (es) | Alquil-piridinas como inhibidores 11-beta de la diabetes | |
MX2010000658A (es) | Derivados de pirimidina 934. | |
NO20062255L (no) | 4-anilino-3-kinolinkarbonitriler for behandling av kronisk myelogenos leukemi (CML) | |
MX2010006882A (es) | Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica. | |
RS54737B1 (sr) | Derivati benzazola kao veznici h4 receptora histamina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |